Soligenix rises on BARDA contract news

|By:, SA News Editor

Soligenix (SNGX.OB +11.2%) jumps after announcing it has received a contract from the Biomedical Advanced Research and Development Authority for the "preclinical and manufacturing development" of the GI ARS treatment OrbeShield.

The initial deal is for two years and can be extended for up to five total years.

The contract is valued at up to $26.3M and will help the company "successfully navigate and complete the FDA approval process." (PR)